Swati Tiwari

Swati Tiwari

Auto-generated profile, based on publicly available information

Swati Tiwari

Department of Molecular Genetics, Biochemistry, and Microbiology, University of Cincinnati , Cincinnati, Ohio

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2016 in Human Gene Therapy
Verified
Journal Article
Closed access
STSwati Tiwari
Swati Tiwari
AHAdrianne Hontz
Adrianne Hontz
CTCatherine E. Terrell
Catherine E. Terrell
PAParitha Arumugam
Paritha Arumugam
MCMarlene Carmo
Marlene Carmo
PMPunam Malik
Punam Malik
Perforin-1 mutations result in a potentially fatal hemophagocytic lymphohistiocytosis (HLH) with heightened immune activation, hypercytokinemia, pancytopenia, and end-organ damage. At present, hematopoietic stem cell (HSC) transplantation is curative, but limited by donor availability and associated mortality, making gene therapy an attractive alternative approach for HLH. We reported that perforin expression driven by cellular promoters in lentiviral (LV) vectors resulted in significant, albeit partial, correction of the inflammatory features in a murine model of HLH. We hypothesized that the level of perforin expression achieved per cell from ectopic moderate-strength cellular promoters (phosphoglycerate kinase gene/perforin-1 gene) is inadequate and thus engineered an LV vector using a viral promoter (MND; a modified Moloney murine leukemia virus long terminal repeat with myeloproliferative sarcoma virus enhancer) containing microRNA126 target sequences to restrict perforin expression in HSCs. We show here that the MND-LV vector restored perforin expression to normal levels in a perforin-deficient human natural killer cell line and perforin gene-corrected Perforin1 −/− transplant recipients, whereas cellular promoters drove only partial correction. On lymphocytic choriomeningitis virus challenge, the clinical scores and survival improved only with the MND-LV vector, but inflammatory markers and cytotoxicity were improved with all LV vectors. Our studies suggest that although moderate levels of expression can result in partial amelioration of the HLH phenotype, high levels of perforin expression per cell are required for complete correction of HLH.

1 May 2015 in Molecular Therapy
Verified
Journal Article
Open access
STSwati Tiwari
Swati Tiwari
AHAdrianne Hontz
Adrianne Hontz
CTCatherine Terrell
Catherine Terrell
PAParitha Arumugam
Paritha Arumugam
MCMarlene Carmo
Marlene Carmo
PMPunam Malik
Punam Malik